The Center for Genetic Engineering and Biotechnology (CIGB), developer of both drugs, said on Twitter that Hermanos Ameijeiras Hospital in this capital, just like in phase I, hosts the new research.

They specified in the same post that at the end of the study, volunteers between 19 and 80 years of age who did not have any drug before or after convalescence will get results of the immune response to natural infection and booster doses.

‘Mambisa’, administered with nasal spray, drop dispenser or a Cuban device with a syringe, is a unique formulation based on the platform of recombinantly- produced antigens, technology with high safety, according to official information.

‘Abdala’, in turn, is the first vaccine against Covid-19 on the island and in Latin America, showing in its phase III trial with three doses, an efficacy of 100 percent to prevent serious conditions and death, and 92.28 percent against symptomatic disease.

On the other hand, 120 individuals from the same group took part last July in phase I of the clinical trial for convalescents with the same drugs.

Prior to this clinical trial, the country began another with the then vaccine candidate ‘Soberana Plus’, from the Finlay Vaccine Institute, which also sought to assess safety, reactogenicity and immunogenicity of a dose in patients recovered from the disease.

Participants, in the same age group, had a history of mild or moderate Covid-19, and of asymptomatic infection. In this phase I clinical trial with Soberana Plus, the drug proved the ability to induce high rates of neutralizing antibodies in convalescent patients.

ef/lcr/mem/nmr